Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI

Citation
Ep. Canet et al., Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI, MAGN RES M, 43(3), 2000, pp. 403-409
Citations number
23
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Journal title
MAGNETIC RESONANCE IN MEDICINE
ISSN journal
07403194 → ACNP
Volume
43
Issue
3
Year of publication
2000
Pages
403 - 409
Database
ISI
SICI code
0740-3194(200003)43:3<403:KCOCAA>2.0.ZU;2-T
Abstract
Recent developments in magnetic resonance imaging (MRI) using specific cont rast media allow the assessment of myocardial perfusion, The purpose of thi s study was to characterize the intravascular properties of a new macromole cular contrast agent, CMD-A2-Gd-DOTA, to evaluate myocardial perfusion, Two groups of isolated pig hearts perfused at various controlled flows were us ed, To demonstrate the intravascular properties of CMD-A2-Gd-DOTA, the agen t was simultaneously injected with 99mTc-labeled red blood cells in five he arts (group 1), Tracer kinetics of both compounds were assessed by coronary sinus effluent sampling, radioactivity counting and concentration determin ation in samples for first-pass time curves measurements, Five other hearts (group 2) were studied using a two-slice turboFLASH sequence on a 1.5-T wh ole-body MRI in order to evaluate first-pass CMD-A2-Gd-DOTA signal intensit y (SI) versus time curves, In group 1,for the studied flows ranging from 0. 8 to 3.1 ml/min(-1) . g(-1), CMD-A2-Gd-DOTA showed first-pass concentration curves typical of an intravascular contrast agent. In group 2, MRI paramet ers, i.e., upslope and mean transit time of SI time curves correlated stron gly with myocardial perfusion, Within the physiologic range of flows, CMD-A 2-Gd-DOTA was able to demonstrate tracer kinetics for in vivo assessment of myocardial perfusion using MRI, (C) 2000 Wiley-Liss, Inc.